Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Phase 1/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin)
administered as an intravenous infusion once every four weeks in combination with other
agent(s) in participants with high-grade serous ovarian cancer (HGSOC, including fallopian
tube and primary peritoneal cancer). This study has an umbrella design. The trial consists of
dose escalation (DES) and expansion (EXP) portions for specific combinations outlined in
various modules. In addition to safety assessments, the pharmacokinetics of the drug will be
assessed along with ADC activity.